CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel diseaseDavid J. Friedman, Simon C. Robson, Beat Künzli et al.|Proceedings of the National Academy of Sciences|2009Cited by 284
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitisHeiko Witt, Thomas Berg, Miklós Sahin‐Tóth et al.|Nature Genetics|2006Cited by 250
Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based Ranking of Marker GenesChristof Winter, Robert Grützmann, Markus W. Büchler et al.|PLoS Computational Biology|2012Cited by 216
Upregulation of CD39/NTPDases and P2 receptors in human pancreatic diseaseBeat Künzli, Simon C. Robson, Pascal O. Berberat et al.|American Journal of Physiology-Gastrointestinal and Liver Physiology|2006Cited by 160
Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancerBeat Künzli, Simon C. Robson, Maria-Isabell Bernlochner et al.|Purinergic Signalling|2011Cited by 124